Previous 10 | Next 10 |
New data from an ongoing open-label Phase 1/2 clinical trial, HGB-206 , evaluating bluebird bio's (NASDAQ: BLUE ) LentiGlobin gene therapy in sickle cell disease (SCD) patients showed a significant treatment benefit. The results were presented at ASH in Orlando. More news on: bluebird ...
99% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with history of VOCs and ACS who had at least six months follow-up, no reports of ACS or serious VOCs at up to 21 months post-treatment Group C patients at six months post...
Bluebird bio (NASDAQ: BLUE ) and licensee Bristol-Myers Squibb (NYSE: BMY ) announce positive topline results from a Phase 2 clinical trial, KarMMa , evaluating CAR T therapy idecabtagene vicleucel (ide-cel) (bb2121) in treatment-resistant multiple myeloma (MM) patients. More news on: b...
Study met its primary endpoint and key secondary endpoint, demonstrating deep and durable responses in a heavily pre-treated multiple myeloma patient population Safety results are consistent with the data presented in CRB-401 study Bristol-Myers Squibb Company (NYSE: BMY) a...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 9, 2019 at 8:00 p.m. ET to review clinical data presented at the 61 st American Society of Hematology Annual Meeting and Exposition. Investors may listen to the call by dialing (844)...
Introduction I have covered companies developing immunotherapy treatments, with a focus on T cell therapies. While I have no doubt T cell therapies will be the next pillar in cancer treatments, current generation of therapies are plagued with various limitations. For example, approved CA...
bluebird bio ( BLUE -0.4% ) tilts lower despite winning an upgrade to Outperform from Market Perform with a $119 price target at SVB Leerink, as analyst Mani Foroohar notes the stock has been cut in half since early March. More news on: bluebird bio, Inc., Healthcare stocks news, ...
CRISPR Therapeutics (NASDAQ: CRSP) made news recently after unveiling some impressive results for its signature gene-editing drug, CTX001. Coupled with an earlier analyst upgrade from Oppenheimer, the news caused shares of CRISPR to surge by more than 25% on Nov. 19. Since then, however, CRI...
Traditional gene therapy has seen numerous challenges during its decades of development, but scientists seem to have finally figured out how to get the treatment to work with regulatory approvals for Novartis ' (NYSE: NVS) Zolgensma and bluebird bio 's (NASDAQ: BLUE) Zynteglo this...
Introduction Cancer is the second leading cause of death globally, with an estimated 17.0 million new cases and 9.5 million deaths in 2018. By 2040, the global burden is expected to grow to 27.5 million new cases and 16.3 million deaths. Although most money in clinical development has ...
News, Short Squeeze, Breakout and More Instantly...
The downtrodden biotech space has kicked off the second half of 2022 with a boom. Hard-hit gene-editing and gene therapy companies in particular have started the back half of the year on the right foot. Underscoring this point, Bluebird Bio (NASDAQ: BLUE) stock has already risen by ...
Bluebird Bio 's (NASDAQ: BLUE) stock motored upward above 24% amid an unusually high volume of trading before pulling back to around 13.3% by noon on Tuesday, likely as a result of a short squeeze . More than 34.6% of its floating shares were held short as of June 15, which puts...